These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 10365093)
1. CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage? Regauer S; Ott A; Berghold A; Beham A J Pathol; 1999 Jan; 187(2):184-90. PubMed ID: 10365093 [TBL] [Abstract][Full Text] [Related]
2. Expression of CD44s and CD44 splice variants in human melanoma. Ranuncolo SM; Ladeda V; Gorostidy S; Morandi A; Varela M; Lastiri J; Loria D; Del Aguila R; Joffé EB; Pallotta G; Puricelli L Oncol Rep; 2002; 9(1):51-6. PubMed ID: 11748454 [TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of expression of cell adhesion molecule (CD44) splice variants: CD44 standard (CD44s) and v5, v6 isoforms in oral leukoplakias: an immunohistochemical study. Godge PY; Poonja LS Indian J Dent Res; 2011; 22(3):493-4. PubMed ID: 22048598 [TBL] [Abstract][Full Text] [Related]
4. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431 [TBL] [Abstract][Full Text] [Related]
5. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. Herold-Mende C; Seiter S; Born AI; Patzelt E; Schupp M; Zöller J; Bosch FX; Zöller M J Pathol; 1996 May; 179(1):66-73. PubMed ID: 8691348 [TBL] [Abstract][Full Text] [Related]
6. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression. Saegusa M; Machida D; Hashimura M; Okayasu I J Pathol; 1999 Nov; 189(3):326-37. PubMed ID: 10547593 [TBL] [Abstract][Full Text] [Related]
7. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928 [TBL] [Abstract][Full Text] [Related]
8. Altered expression of CD44 and variant isoforms in human adenocarcinoma of the endocervix during progression. Lu D; Tawfik O; Pantazis C; Hobart W; Chapman J; Iczkowski K Gynecol Oncol; 1999 Oct; 75(1):84-90. PubMed ID: 10502431 [TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse. Beham-Schmid C; Heider KH; Hoefler G; Zatloukal K J Pathol; 1998 Dec; 186(4):383-9. PubMed ID: 10209487 [TBL] [Abstract][Full Text] [Related]
10. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576 [TBL] [Abstract][Full Text] [Related]
11. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. Müller W; Schneiders A; Heider KH; Meier S; Hommel G; Gabbert HE J Pathol; 1997 Oct; 183(2):222-7. PubMed ID: 9390037 [TBL] [Abstract][Full Text] [Related]
12. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Nguyen VN; Mirejovský T; Melinová L; Mandys V Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866 [TBL] [Abstract][Full Text] [Related]
13. Expression of CD44 variant isoforms in malignant melanoma. Seiter S; Schadendorf D; Herrmann K; Schneider M; Rösel M; Arch R; Tilgen W; Zöller M Clin Cancer Res; 1996 Mar; 2(3):447-56. PubMed ID: 9816190 [TBL] [Abstract][Full Text] [Related]
14. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228 [TBL] [Abstract][Full Text] [Related]
15. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. Ramasami S; Kerr KM; Chapman AD; King G; Cockburn JS; Jeffrey RR J Pathol; 2000 Dec; 192(4):427-32. PubMed ID: 11113858 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of CD44 molecule in renal cell carcinoma. Lucin K; Matusan K; Dordević G; Stipić D Croat Med J; 2004 Dec; 45(6):703-8. PubMed ID: 15578803 [TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer. Kawano T; Nakamura Y; Yanoma S; Kubota A; Furukawa M; Miyagi Y; Tsukuda M Auris Nasus Larynx; 2004 Mar; 31(1):35-41. PubMed ID: 15041052 [TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study. Morris SF; O'Hanlon DM; McLaughlin R; McHale T; Connolly GE; Given HF Eur J Surg Oncol; 2001 Sep; 27(6):527-31. PubMed ID: 11520083 [TBL] [Abstract][Full Text] [Related]
19. Expression of CD44 standard and isoforms in human breast cancer xenografts and shedding of soluble forms into serum of nude mice. Fichtner I; Dehmel A; Naundorf H; Finke LH Anticancer Res; 1997; 17(5A):3633-45. PubMed ID: 9413216 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of immunohistochemically detected CD44 expression in patients with carcinoma of the vulva. Tempfer C; Gitsch G; Haeusler G; Reinthaller A; Koelbl H; Kainz C Cancer; 1996 Jul; 78(2):273-7. PubMed ID: 8674003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]